Chapter
Biogen’s Alzheimer's Drug Controversy
01:05 - 06:54 (05:48)
Biogen stopped a trial for an Alzheimer's drug after negative results, only to surprisingly refile nine months later with data showing those on the highest dose showed a 23% decline in the progression of their Alzheimer's. However, critics argue that the results may not be statistically significant, and therefore do not provide sufficient evidence that the drug works.
Clips
The speaker observes the erratic and rapidly changing weather patterns in Europe, proving its susceptibility to climate change.
01:05 - 03:38 (02:33)
Climate Change
Summary
The speaker observes the erratic and rapidly changing weather patterns in Europe, proving its susceptibility to climate change. Meanwhile, three members of the FDA's advisory panel resign as they are not willing to approve a drug with a low efficacy.
ChapterBiogen’s Alzheimer's Drug Controversy
EpisodeE35: Biogen's controversial Alzheimer's drug approval, the billionaire space race, real estate, Bitcoin & more
PodcastAll-In with Chamath, Jason, Sacks & Friedberg
Biogen stopped the trial, they had this negative outcome and Biogen got beat up for it.
03:38 - 06:54 (03:15)
Business
Summary
Biogen stopped the trial, they had this negative outcome and Biogen got beat up for it.